Back to Search
Start Over
Tofacitinib as treatment for refractory dermatomyositis: A retrospective study from 2 academic medical centers.
- Source :
-
Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2022 Feb; Vol. 86 (2), pp. 423-425. Date of Electronic Publication: 2021 Jul 08. - Publication Year :
- 2022
-
Abstract
- Competing Interests: Conflicts of interest Dr Vleugels is a principal investigator for Pfizer. Dr Merola is a consultant and/or investigator for Abbvie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Celgene, Sanofi-Regeneron, Biogen, Pfizer, and Leo Pharma. If compensation is received, it is considered honorarium. Drs Min, Alsarheed, Kassamali, Mazori, Cobos, and LaChance and Author Schaefer have no conflicts of interest to declare.
Details
- Language :
- English
- ISSN :
- 1097-6787
- Volume :
- 86
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Journal of the American Academy of Dermatology
- Publication Type :
- Editorial & Opinion
- Accession number :
- 34246697
- Full Text :
- https://doi.org/10.1016/j.jaad.2021.07.003